Boehringer Ingelheim experiments with open-access chemical probes

Nature Reviews Drug Discovery 17, 7 (2018). doi:10.1038/nrd.2017.269 Author: Asher Mullard Boehringer Ingelheim launched a platform to share well-characterized preclinical compounds with the biomedical community. These can be used as probes to explore mechanistic and phenotypic biology.The company is currently offering nearly 20 molecular probes through its opnME portal for free, without intellectual property
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research